MGI Tech Co., Ltd. (MGI), a subsidiary of BGI Group, is committed to enabling effective and affordable healthcare solutions for all. Based on its proprietary technology, MGI produces sequencing devices, equipment, consumables and reagents to support life science research, medicine and healthcare.
MGI’s multi-omics platforms include genetic sequencing, mass spectrometry and medical imaging. Providing real-time, comprehensive, life-long solutions, its mission is to develop and promote advanced life science tools for future healthcare.
MegaBOLT adopts the heterogeneous computing system of CPU and FPGA, which greatly improves the analysis speed. It shortens the 100 Gbp WGS analysis duration to 2 hours and 6 Gbp WES analysis duration to 10 minutes.
BGISEQ-50 and MGIUS-R3 independently
developed by MGI won two awards of iF Design Award in Germany for their
breakthrough function and exquisite design in February 2018.
Two new sequencers for more power and lower cost, as well as a highly integrated modular NGS workstation and a remote robotic ultrasound system for exploring more possibility of the future.
Technology and intelligence come together perfectly in this epoch-making clinical trial that enhances the separation and enrichment efficiency by as much as 100,000 times, with a user-oriented, fully-automated, real-time smart cell-seeking technology. The tumor has nowhere to hide!
MGI receied ISO 13485 approval.
The mobile workstation allows for on-site screening for echinococcosis in remote areas, thus providing residents in these areas with improved and convenient testing services.
Broad array of applications with no constraints in terms of space. Suitable for use at low-pressure, high-altitude environments. Multiple integrated functions are enclosed within its compact and simple structure, and its small footprint makes for easy placement.
MGI Tech has complete ownership of intellectual property rights to the device. It can satisfy all clinical needs, and at full speed, can complete the entire sequencing process within 24 hours. BGISEQ-500 has received CFDA and CE approval successively. Supports the development of precise medicine and brings the benefits of gene technology to the people.
The Revolocity is a fully-integrated "super sequencer", with its first users being Mater, a health services provider in Australia, and the Nijmegen University Medical Center in the Netherlands.
The system was approved by the State Food and Drug Administration in 2014, and this development generated much market buzz for related stocks.
Intense industry competition made us even more determined to acquire the listed company Complete Genomics. We have been able to reduce costs right from the inception stage by utilizing CG's cutting-edge biotechnologies and instrument technologies.